- TNX-901 is a humanized IgG1 monoclonal antibody that binds to IgE,
thereby blocking binding to high affinity Fce receptors on the mast
cells and basophils, which prevents allergy-mediator release.
- TNX-901 is well tolerated, with local injection site reactions being
the biggest complaint. No lab abnormalities were reported with the study.
- Unfortunately, there were no objective measures to the oral food challenges.
It is difficult to account for the amount of anxiety seen in the subjects,
which may have contributed to premature cessation of the oral food challenges,
and may also account for the notable placebo effect.
- TNX-901 is no longer available due to an agreement between a consortium
of drug companies, but a very similar compound, Omalizumab (Xolair),
is available. Omalizumab is currently approved for use with severe persistent
asthma, and is in phase II clinical trials for use with peanut allergies.
- Leung D, Sampson H, et al. Effect of Anti-IgE Therapy in Patients
with Peanut Allergy. N Engl J Med 2003; 348: 986-93.
- Merz B. Studying Peanut Anaphylaxis. N Engl J Med 2003; 348:
- Metzger H. Two Approaches to Peanut Allergy. N Engl J Med 2003;
- Sampson HJ. Update on food allergy. J Allergy Clin Immunol
2004; 113: 805-19.
- "Omalizumab." Physicians' Desk Reference, 2005 ed.